Jan. 3, 2022 — The FDA on Monday licensed the primary COVID-19 vaccine booster dose for American adolescents ages 12 to fifteen.
Apart from updating the authorization for the Pfizer COVID-19 vaccine, the company additionally shortened the really helpful time between a second dose and the booster to five months or extra, primarily based on new proof. As well as, a 3rd major sequence dose is now licensed for sure immunocompromised kids 5 years to 11 years previous. Full particulars can be found in an FDA news release.
The amended emergency use authorization (EUA) solely applies to the Pfizer vaccine, mentioned performing FDA Commissioner Janet Woodcock, MD.
“Simply to verify each everybody is evident on this, proper now: When you obtained [Johnson & Johnson’s one-dose vaccine], you get a booster after 2 months. When you obtained Moderna, you will get a booster at 6 months or past,” she mentioned throughout a media briefing.
What’s new, she mentioned, is “in case you obtained Pfizer as your major sequence, you will get a booster at 5 months or past.”
A Decrease Danger of Myocarditis?
Requested about issues concerning the threat of myocarditis with vaccination within the 12- to 15-year age group, Woodcock mentioned they count on it will be “extraordinarily uncommon with the third dose.”
“We’ve the real-world proof from the Israeli expertise to assist us with that evaluation,” she mentioned.
The information thus far constantly factors to the next threat of myocarditis after a second mRNA vaccine dose amongst males, from youngsters to 30-year-olds, with a peak at about 16 to 17 years of age, Peter Marks, MD, PhD, director of the FDA’s Middle for Biologics Analysis and Analysis, mentioned in the course of the media name.
The chance of myocarditis is about 2 to three occasions increased after a second vaccine dose, in comparison with a booster shot, Marks mentioned, primarily based on out there knowledge. It could be associated to the nearer dose timing of the second dose versus a 3rd, he added.
“The inference right here is that on the chance of myocarditis with third doses within the 12- to 15-year age vary is more likely to be fairly acceptable,” he mentioned.
Marks additionally identified that almost all circumstances of myocarditis clear up rapidly.
“We’re not seeing long-lasting results. That is to not say that we do not care about this and that it is not necessary,” he mentioned.
“However what it’s saying is that within the setting of an amazing variety of Omicron and Delta circumstances on this nation, the potential advantages of getting vaccinated on this age group outweigh that threat,” Marks mentioned. “We are able to have a look at that risk-benefit and nonetheless really feel comfy.”
He mentioned that “the actually overwhelming majority of those circumstances, 98%, have been delicate” — proven by a 1-day median hospital keep.
Even so, the FDA plans to proceed monitoring for the chance of myocarditis “very intently,” he mentioned.
Curiously, swollen underarm lymph nodes had been seen extra steadily after the booster dose than after the second dose of a two-dose major sequence, the FDA mentioned.
Lowering the time between major vaccination with the Pfizer vaccine — two preliminary doses — and the booster shot from 6 months to five months relies on lowering efficacy knowledge that the drugmaker submitted to the FDA.
The 5-month interval was evaluated in a study from Israel revealed Dec. 21 in The New England Journal of Drugs.
Mixing and Matching Vaccines
Much less clear in the mean time is steering about boosters for individuals who opted to combine and match their major vaccine sequence.
“There was a mix-and-match examine that was performed which confirmed that in some circumstances, the blending and matching … of an adenoviral report vaccine and an mRNA vaccine appear to offer an excellent immune response,” Marks mentioned.
As soon as extra knowledge is available in on mixing and matching, “we’ll analyze them after which probably make suggestions,” he mentioned.
‘It is Not Too Late’
No federal authorities media briefing on COVID-19 could be full and not using a plea for the unvaccinated to get immunized.
“We’re speaking quite a bit about boosters proper now, but it surely’s not too late for many who haven’t gotten a vaccine to get a vaccine,” Marks mentioned, referring to the tens of tens of millions of Individuals who stay unvaccinated at the start of 2022.
“We all know from our earlier research that even a single dose of the vaccine — and doubtless two doses — will help forestall the worst outcomes from COVID-19, together with hospitalization and dying.”